Key Points
A type I IFN transcriptional profile is upregulated in SLE B cells.
Human B cells express type I IFN genes in response to IFN-λ (type III IFN).
IFN-λ may enhance TLR7-mediated B cell activation and PC differentiation in SLE.
Abstract
Type I IFN is essential for viral clearance but also contributes to the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), via aberrant nucleic acid–sensing pathways, leading to autoantibody production. Type III IFN (IFN-λ) is now appreciated to have a nonredundant role in viral infection, but few studies have addressed the effects of IFN-λ on immune cells given the more restricted expression of its receptor primarily to the epithelium. In this study, we demonstrate that B cells display a prominent IFN gene expression profile in patients with lupus. Serum levels of IFN-λ are elevated in SLE and positively correlate with B cell subsets associated with autoimmune plasma cell development, including CD11c+T-bet+CD21− B cells. Although B cell subsets express all IFN receptors, IFNLR1 strongly correlates with the CD11c+CD21− B cell expansion, suggesting that IFN-λ may be an unappreciated driver of the SLE IFN signature and B cell abnormalities. We show that IFN-λ potentiates gene transcription in human B cells typically attributed to type I IFN as well as expansion of T-bet–expressing B cells after BCR and TLR7/8 stimulation. Further, IFN-λ promotes TLR7/8-mediated plasmablast differentiation and increased IgM production. CD11c+ B cells demonstrate IFN-λ hyperresponsive signaling compared with other B cell subsets, suggesting that IFN-λ accelerates plasma cell differentiation through this putative extrafollicular pathway. In summary, our data support type III IFN-λ as a cytokine promoting the Ab-secreting cell pool in human viral and autoimmune disease.
Footnotes
This work was supported by the Rheumatology Research Foundation (Scientist Development Award 060631-02 to J.L.B.), National Institute of Arthritis and Musculoskeletal and Skin Diseases (Accelerated Medicines Partnership Grant 1UH2-AR-067690 to J.H.A.), and the Bertha and Louis Weinstein Research Fund (to J.H.A.).
The gene expression profiles and reads presented in this article have been submitted to the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE175913.
The online version of this article contains supplemental material.
- Received April 7, 2021.
- Accepted September 17, 2021.
- Copyright © 2021 by The American Association of Immunologists, Inc.
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.